December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

12.97 +0.03 (+0.19%)
Streaming Delayed Price Updated: 3:11 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
1 Small-Cap Stock to Target This Week and 2 That Underwhelm
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
News headline image
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
News headline image
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
3 Healthcare Stocks We’re Skeptical Of
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand,... 
Via StockStory
Topics Stocks
News headline image
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
Represents second complex respiratory therapeutic product approval in Q4 2025 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal to Participate in Upcoming Investor Conferences
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares? ↗
The pharmaceutical company has experienced sales growth over the past five years. 
Via The Motley Fool
News headline image
Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated... 
Via StockStory
Topics Economy
News headline image
Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs ↗
One executive’s option-linked sale may look large on paper, but the broader context tells a more nuanced story. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks
Looking back on generic pharmaceuticals stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Amneal (NASDAQ:AMRX) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Russell 2000 Stocks with Warning Signs
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these... 
Via StockStory
News headline image
Amneal Receives U.S. FDA Approval for Iohexol Injection
First-to-market complex injectable with expected launch in Q1 2026 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
3 Stocks Under $50 We Steer Clear Of
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
News headline image
Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid... 
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
3 Value Stocks We Find Risky
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
News headline image
Why Amneal (AMRX) Stock Is Up Today
Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 8.9% in the afternoon session after the company reported strong third-quarter financial results that surpassed expectations... 
Via StockStory
News headline image
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Q3 2025 Earnings: EPS Beats Estimates, Stock Surges on Raised Guidance ↗
Amneal Pharmaceuticals Q3 2025 earnings beat profit estimates, driving a stock surge. The company also raised its full-year guidance for EBITDA and EPS. 
Via Chartmill
Topics Earnings
News headline image
Amneal (NASDAQ:AMRX) Beats Q3 Sales Expectations, Stock Soars
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 11.7% year on year to $784.5 million. The company’s... 
Via StockStory
News headline image
Amneal Reports Third Quarter 2025 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
Company’s first metered-dose inhalation (MDI) product and establishes a new growth vector for the Affordable Medicines segment 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Earnings: What To Look For From AMRX
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results this Thursday before the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
News headline image
Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
3 Cash-Producing Stocks with Questionable Fundamentals
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks We Find Risky
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
News headline image
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs ↗
The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns. 
Via Benzinga
Topics Government World Trade
News headline image
1 Small-Cap Stock with Competitive Advantages and 2 We Turn Down
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
News headline image
Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)
From Kashiv BioSciences, LLC and Amneal Pharmaceuticals, Inc. and Alvotech and Advanz Pharma
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.